Loading...
•
Sep 30, 2020
Insulet Q3 2020 Earnings Report
Insulet reported a revenue increase of 22% year-over-year, driven by Omnipod revenue growth of 20%.
Key Takeaways
Insulet Corporation reported strong financial results for the third quarter of 2020, with revenue reaching $234.0 million, a 21.8% increase compared to the previous year. The company's performance exceeded expectations, driven by innovation and a recurring revenue model. Insulet raised its full-year revenue outlook and anticipates delivering its fifth consecutive year of 20% growth.
Third quarter revenue reached $234.0 million, up 21.8% year-over-year.
Total Omnipod revenue was $212.1 million, a 19.7% increase.
Net income amounted to $11.6 million, or $0.17 per diluted share.
Adjusted EBITDA was $42.3 million, representing 18.1% of revenue.
Insulet
Insulet
Insulet Revenue by Segment
Revenue by Segment
U.S. Omnipod Revenue
CapyFin.comInternational Omnipod Revenue
CapyFin.comDrug Delivery Revenue
CapyFin.com Forward Guidance
For the quarter ending December 31, 2020, the Company expects revenue growth of 7% to 11%.
Positive Outlook
- Total Omnipod revenue growth of 10% to 14%
- U.S. Omnipod revenue growth of 10% to 14%
- International Omnipod revenue growth of 10% to 14%
Challenges Ahead
- Drug Delivery decline of 17% to 23%
Revenue & Expenses
Visualization of income flow from segment revenue to net income